26-01-2007: Affymetrix Inc. and Vanderbilt-Ingram Cancer Center announced that they have entered into a three-year translational research collaboration to analyze genomic information across a large number of patient samples. Under terms of the agreement, researchers at Vanderbilt-Ingram and Vanderbilt University Medical Center will use Affymetrix GeneChip(R) microarray technology to develop new applications for translational research projects, focusing on disease areas such as cancer and HIV/AIDS. The HIV/AIDS translational research project will aim to help clinicians avoid the often irreversible and costly complications of therapy. The results of this study will potentially help clinicians select the most appropriate drug therapy for each patient, avoiding those most likely to cause toxicity. Such a tool could have important applications for HIV/AIDS treatment in both affluent and resource-limited settings, and for other diseases.
"A number of important translational projects are underway, ranging from cancer research to HIV/AIDS drug toxicities to age-related macular degeneration," said Jeff Canter M.D., M.P.H., assistant professor of molecular physiology and biophysics at the Center for Human Genetics Research at Vanderbilt University Medical Center. "This is a very exciting time because new sequencing technologies allow us to explore real-world applications of discoveries from the revolution in genetics that until now have been confined to the laboratory."
This is where you can add this news to your personal favourites
Affymetrix, Inc., and eBioscience, Inc. announced they have amended their existing definitive agreement dated November 29, 2011 under which Affymetrix will acquire eBioscience. Under the terms of the amended agreement, Affymetrix will acquire eBioscience for $315 million in cash subject to ... more
Composed of more than 4 billion nucleotides, a draft sequence of the Neandertal genome won the 2010 Newcomb Cleveland Prize of the American Association for the Advancement of Science (AAAS).The Association's oldest prize, now supported by Affymetrix, the Newcomb Cleveland Prize annually rec ... more
Roche NimbleGen Inc., a company of Roche Applied Science, and Affymetrix Inc. announced that they have expanded the terms of the license to a number of Affymetrix patents originally granted in October 2006. The expanded license now provides certain diagnostic rights for array-based DNA copy ... more
Affymetrix' GeneChip® technology was invented in the late 1980's by a team of scientists led by Stephen P.A. Fodor, Ph.D. The theory behind their work was revolutionary - a notion that semiconductor manufacturing techniques could be united with advances in combinatorial chemistry to build v ... more
Affymetrix GeneChip(R) microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more com ... more
Affymetrix is adding new genetic analysis technologies to streamline workflows and help you revolutionize life.
After pioneering the microarray technology Affymetrix is evolving into a provider of scalable,
innovative genomic analysis tools and reagents for discovery, exploration, validati ... more